<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03686488</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-19477</org_study_id>
    <nct_id>NCT03686488</nct_id>
  </id_info>
  <brief_title>TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma</brief_title>
  <official_title>A Phase II Study of TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if the combination of TAS 102 and Ramucirumab is&#xD;
      safe and effective in patients with advanced, refractory gastric or gastroesophageal junction&#xD;
      (GEJ) adenocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 20, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>6 months</time_frame>
    <description>Overall survival defined as the time from starting on trial to date of death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with at least one adverse event</measure>
    <time_frame>4 weeks after end of study participation</time_frame>
    <description>Frequency and severity of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>6 months</time_frame>
    <description>Response Evaluation Criteria in Solid Tumors (RECIST) based response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>6 months</time_frame>
    <description>PFS, defined as the duration of time from start of treatment to time of progression or death, whichever comes first.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Gastric Adenocarcinoma</condition>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>TAS 102 and Ramucirumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAS 102 (Lonsurf) and Ramucirumab 10 MG/ML Intravenous Solution (CYRAMZA) administered concurrently.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAS 102</intervention_name>
    <description>TAS 102 35 mg will be administered orally twice daily every 2 weeks.</description>
    <arm_group_label>TAS 102 and Ramucirumab</arm_group_label>
    <other_name>Lonsurf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramucirumab 10 MG/ML Intravenous Solution [CYRAMZA]</intervention_name>
    <description>Ramucirumab 8 miligrams/kilogram will be administered as a 60 minute intravenous (IV) infusion every 2 weeks.</description>
    <arm_group_label>TAS 102 and Ramucirumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of gastric and GEJ adenocarcinoma.&#xD;
&#xD;
          -  Measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumors&#xD;
             (RECIST) 1.1. Stage IV or recurrent disease is required. An irradiated lesion is&#xD;
             considered evaluable only if it has shown enlargement since the completion of last&#xD;
             radiation.&#xD;
&#xD;
          -  Participants must have received and progressed with prior therapy. Prior therapy with&#xD;
             ramucirumab is not allowed. Participants must have recovered from the toxic effects of&#xD;
             the previous anti-cancer chemotherapy (with the exception of alopecia).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance score 0 or 1&#xD;
&#xD;
          -  Estimated life expectancy &gt; 3 months&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal function as assessed by the following:&#xD;
             Hemoglobin &gt; 8.0 g/dl, Absolute neutrophil count (ANC) &gt; 1,000/mm3 independent of&#xD;
             growth factor support, Platelet count &gt; 100,000/mm3, Total bilirubin &lt; 1.5 times upper&#xD;
             limits of normal (ULN) unless bilirubin rise is due to Gilbert's syndrome or of&#xD;
             non-hepatic origin, aspartate transaminase (AST), alanine transaminase (ALT) and&#xD;
             Alkaline Phosphatase ≤2.5 times the ULN ( ≤5 x ULN for patients with liver&#xD;
             involvement), Creatinine clearance ≥ 30 ml/min.&#xD;
&#xD;
          -  Participants must not have had chemotherapy,major surgery, monoclonal antibody therapy&#xD;
             or experimental therapy within the 28 days prior to the start of TAS 102&#xD;
             administration.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test performed&#xD;
             within 7 days prior to the start of study drug. Post-menopausal women (defined as no&#xD;
             menses for at least 1 year) and surgically sterilized women are not required to&#xD;
             undergo a pregnancy test.&#xD;
&#xD;
          -  Participants (men and women) of childbearing potential must agree to use adequate&#xD;
             contraception beginning at the signing of the informed consent form until at least 4&#xD;
             months for both females and males after the last dose of study drug. The definition of&#xD;
             adequate contraception will be based on the judgment of the principal investigator or&#xD;
             a designated associate.&#xD;
&#xD;
          -  Participants must be able to understand and be willing to sign the written informed&#xD;
             consent form. A signed informed consent form must be appropriately obtained prior to&#xD;
             the conduct of any trial-specific procedure. Subjects must be willing and able to&#xD;
             comply with scheduled visits, treatment schedule, laboratory testing, and other study&#xD;
             requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with active Central Nervous System (CNS) metastases are excluded. If CNS&#xD;
             metastases are treated and participants are at neurologic baseline for at least 2&#xD;
             weeks prior to enrollment, they will be eligible but will need a Brain MRI prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  Women who are pregnant or breast-feeding.&#xD;
&#xD;
          -  Prior therapy with ramucirumab, bevacizumab, regorafenib or TAS 102.&#xD;
&#xD;
          -  Previous or concurrent cancer within 3 years prior to treatment start EXCEPT for&#xD;
             curatively treated cervical cancer in situ, non-melanoma skin cancer, superficial&#xD;
             bladder 15 tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor&#xD;
             invades lamina propria)].&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic BP &gt;140 mm Hg or diastolic BP &gt;90 mm Hg on&#xD;
             repeated measurement despite optimal medical management)&#xD;
&#xD;
          -  Any hemorrhage or bleeding event ≥ NCI CTCAE Grade 3 within 4 weeks prior to start of&#xD;
             study medication.&#xD;
&#xD;
          -  Any hemorrhage or bleeding event ≥ NCI CTCAE Grade 3 within 4 weeks prior to start of&#xD;
             study medication.&#xD;
&#xD;
          -  Persistent proteinuria ≥ Grade 3 on repeated measurement.&#xD;
&#xD;
          -  Substance abuse, medical, psychological or social conditions that may interfere with&#xD;
             the patient's participation in the study or evaluation of the study results.&#xD;
&#xD;
          -  Participants with an arterial thrombotic or thromboembolic event within 12 months of&#xD;
             informed consent.&#xD;
&#xD;
          -  Ascites, pleural effusion, or pericardial fluid requiring drainage in the last 4 weeks&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) infection or current chronic or&#xD;
             active hepatitis B or C infection requiring treatment with antiviral therapy.&#xD;
&#xD;
          -  Clinically significant cardiovascular disease such as unstable angina, uncontrolled or&#xD;
             symptomatic arrhythmia, congestive heart failure, any Class 3 or 4 cardiac disease as&#xD;
             defined by the New York Heart Association Functional Classification, or history of&#xD;
             myocardial infarction within 6 months prior to first dose with study drug.&#xD;
&#xD;
          -  Unable to swallow capsules or disease significantly affecting gastrointestinal&#xD;
             function and/or inhibiting small intestine absorption such as; malabsorption syndrome,&#xD;
             resection of the small bowel, or poorly controlled inflammatory bowel disease&#xD;
             affecting the small intestine.&#xD;
&#xD;
          -  Child-Pugh B cirrhosis (or worse) or a history of hepatic encephalopathy&#xD;
&#xD;
          -  History of stroke or intracranial hemorrhage within 6 months prior to enrollment.&#xD;
&#xD;
          -  Any illness or medical conditions that are unstable or could jeopardize the safety of&#xD;
             the patient and his/her compliance in the study.&#xD;
&#xD;
          -  Major surgery or a wound that has not fully healed within 4 weeks of enrollment.&#xD;
&#xD;
          -  Patients who need anticancer chemotherapy other than the study drugs during the study&#xD;
             or within 4 weeks of study enrollment. Anti-cancer therapy is defined as any agent or&#xD;
             combination of agents with clinically proven anti-tumor activity administered by any&#xD;
             route with the purpose of affecting the malignancy, either directly or indirectly,&#xD;
             including palliative and therapeutic endpoints.&#xD;
&#xD;
          -  Patients who need hormonal therapy during the study or within 2 weeks of first study&#xD;
             enrollment.&#xD;
&#xD;
          -  Patients who need radiotherapy to target lesions during study or within 2 weeks of&#xD;
             enrollment.&#xD;
&#xD;
          -  Patients who had bone marrow transplant or stem cell rescue.&#xD;
&#xD;
          -  Patients who need investigational drug therapy outside of this trial during or within&#xD;
             4 weeks of first study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dae W Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://moffitt.org/clinical-trials-research/clinical-trials/</url>
    <description>Moffitt Cancer Center Clinical Trials Website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 25, 2018</study_first_submitted>
  <study_first_submitted_qc>September 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2018</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramucirumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

